<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36474858</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2688-2663</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Dec</Month></PubDate></JournalIssue><Title>MedComm</Title><ISOAbbreviation>MedComm (2020)</ISOAbbreviation></Journal><ArticleTitle>Mixed formulation of mRNA and protein-based COVID-19 vaccines triggered superior neutralizing antibody responses.</ArticleTitle><Pagination><StartPage>e188</StartPage><MedlinePgn>e188</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e188</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/mco2.188</ELocationID><Abstract><AbstractText>Integrating different types of vaccines into a singular immunization regimen is an effective and accessible approach to strengthen and broaden the immunogenicity of existing coronavirus disease 2019 (COVID-19) vaccine candidates. To optimize the immunization strategy of the novel mRNA-based vaccine and recombinant protein subunit vaccine that attracted much attention in COVID-19 vaccine development, we evaluated the immunogenicity of different combined regimens with the mRNA vaccine (RNA-RBD) and protein subunit vaccine (PS-RBD) in mice. Compared with homologous immunization of RNA-RBD or PS-RBD, heterologous prime-boost strategies for mRNA and protein subunit vaccines failed to simultaneously enhance neutralizing antibody (NAb) and Th1 cellular response in this study, showing modestly higher serum neutralizing activity and antibody-dependent cell-mediated cytotoxicity for "PS-RBD prime, RNA-RBD boost" and robust Th1 type cellular response for "RNA-RBD prime, PS-RBD boost". Interestingly, immunizing the mice with the mixed formulation of the two aforementioned vaccines in various proportions further significantly enhanced the NAb responses against ancestral, Delta, and Omicron strains and manifested increased Th1-type responses, suggesting that a mixed formulation of mRNA and protein vaccines might be a more prospective vaccination strategy. This study provides basic research data on the combined vaccination strategies of mRNA and protein-based COVID-19 vaccines.</AbstractText><CopyrightInformation>© 2022 The Authors. MedComm published by Sichuan International Medical Exchange &amp; Promotion Association (SCIMEA) and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Xujia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Chaoqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Bopei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junzhi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products Beijing People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>MedComm (2020)</MedlineTA><NlmUniqueID>101769925</NlmUniqueID><ISSNLinking>2688-2663</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19 vaccine</Keyword><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">Th1 response</Keyword><Keyword MajorTopicYN="N">heterologous prime‐boost</Keyword><Keyword MajorTopicYN="N">neutralizing antibody</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>7</Day><Hour>2</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36474858</ArticleId><ArticleId IdType="pmc">PMC9717706</ArticleId><ArticleId IdType="doi">10.1002/mco2.188</ArticleId><ArticleId IdType="pii">MCO2188</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Su S, Du L, Jiang S. Learning from the past: development of safe and effective COVID‐19 vaccines. Nat Rev Microbiol. 2021;19(3):211‐219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566580</ArticleId><ArticleId IdType="pubmed">33067570</ArticleId></ArticleIdList></Reference><Reference><Citation>
Team VGCVT
. COVID19 vaccine tracker. 2022.  Accessed October 28, 2022. https://covid19.trackvaccines.org/
</Citation></Reference><Reference><Citation>Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated whole‐virion SARS‐CoV‐2 vaccine (CoronaVac): interim results of a double‐blind, randomized, placebo‐controlled, phase 3 trial in Turkey. The Lancet. 2021;398(10296):213‐222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8266301</ArticleId><ArticleId IdType="pubmed">34246358</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single‐dose Ad26.COV2.S vaccine against COVID‐19. N Engl J Med. 2021;384(23):2187‐2201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy RB. Efficacy of an adenovirus type 5 vectored SARS‐CoV‐2 vaccine. The Lancet. 2022;399(10321):212‐213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8700275</ArticleId><ArticleId IdType="pubmed">34953524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot‐to‐lot immunogenicity of an inactivated SARS‐CoV‐2 vaccine (BBV152): interim results of a randomised, double‐blind, controlled, phase 3 trial. The Lancet. 2021;398(10317):2173‐2184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8584828</ArticleId><ArticleId IdType="pubmed">34774196</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L, Gao L, Tao L, et al. Efficacy and safety of the rbd‐dimer‐based COVID‐19 vaccine ZF2001 in adults. N Engl J Med. 2022;386(22):2097‐2111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127771</ArticleId><ArticleId IdType="pubmed">35507481</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. COVID‐19 vaccine breakthrough infections reported to CDC — United States, January 1–April 30, 2021. N Engl J Med. 2020;383(27):2603‐2615.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergwerk M, Gonen T, Lustig Y, et al. COVID‐19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474‐1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S. Heterologous prime‐boost vaccination. Curr Opin Immunol. 2009;21(3):346‐351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3743086</ArticleId><ArticleId IdType="pubmed">19500964</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Parker C, Taaffe J, Solórzano A, García‐Sastre A, Lu S. Heterologous HA DNA vaccine prime–inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine. 2008;26(29‐30):3626‐3633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2802517</ArticleId><ArticleId IdType="pubmed">18538900</ArticleId></ArticleIdList></Reference><Reference><Citation>Excler JL, Kim JH. Novel prime‐boost vaccine strategies against HIV‐1. Expert Rev Vaccin. 2019;18(8):765‐779.</Citation><ArticleIdList><ArticleId IdType="pubmed">31271322</ArticleId></ArticleIdList></Reference><Reference><Citation>Aleshin SE, Timofeev AV, Khoretonenko MV, et al. Combined prime‐boost vaccination against tick‐borne encephalitis (TBE) using a recombinant vaccinia virus and a bacterial plasmid both expressing TBE virus non‐structural NS1 protein. BMC Microbiol. 2005;5:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1187892</ArticleId><ArticleId IdType="pubmed">16076390</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Arthos J, Lawrence JM, et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR‐FL primary isolate of human immunodeficiency virus type 1. J Virol. 2005;79(12):7933‐7937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1143658</ArticleId><ArticleId IdType="pubmed">15919951</ArticleId></ArticleIdList></Reference><Reference><Citation>Burm R, Maravelia P, Ahlen G, et al. Novel prime‐boost immune‐based therapy inhibiting both hepatitis B and D virus infections. Published online: August 17, 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10176361</ArticleId><ArticleId IdType="pubmed">35977815</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime‐boost schedules with an adenoviral vectored and mRNA COVID‐19 vaccine (Com‐COV): a single‐blind, randomised, non‐inferiority trial. The Lancet. 2021;398(10303):856‐869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8346248</ArticleId><ArticleId IdType="pubmed">34370971</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku CI, Champney ER, Normark J, et al. Broad anti–SARS‐CoV‐2 antibody immunity induced by heterologous ChAdOx1/mRNA‐1273 vaccination. Science. 2022;375:1041‐1047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939765</ArticleId><ArticleId IdType="pubmed">35143256</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros‐Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against SARS‐CoV‐2 variants after heterologous and homologous ChAdOx1 nCoV‐19/BNT162b2 vaccination. Nature medicine. 2021;27(9):1525‐1529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440184</ArticleId><ArticleId IdType="pubmed">34262158</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Liao Y, Jiang G, et al. Immunological evaluation of an mRNA vaccine booster in individuals fully immunized with an inactivated SARS‐CoV‐2 vaccine. Clin Transl Med. 2022;12(6):e875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9178391</ArticleId><ArticleId IdType="pubmed">35678117</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos GRF, Almeida NBF, Filgueiras PS, et al. Booster dose of BNT162b2 after two doses of CoronaVac improves neutralization of SARS‐CoV‐2 Omicron variant. Commun Med. 2022;2:76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9242982</ArticleId><ArticleId IdType="pubmed">35784447</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen G, Jungsomsri P, Sangwongwanich J, et al. Immunogenicity and reactogenicity after heterologous prime‐boost vaccination with CoronaVac and ChAdox1 nCov‐19 (AZD1222) vaccines. Hum Vaccin Immunother. 2022;18(5):2052525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115782</ArticleId><ArticleId IdType="pubmed">35323079</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Mao Q, An C, et al. Heterologous prime‐boost: breaking the protective immune response bottleneck of COVID‐19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629‐637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009122</ArticleId><ArticleId IdType="pubmed">33691606</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Bi Y, Xiao H, et al. A novel DNA and protein combination COVID‐19 vaccine formulation provides full protection against SARS‐CoV‐2 in rhesus macaques. Emerg Microbes Infect. 2021;10(1):342‐355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928010</ArticleId><ArticleId IdType="pubmed">33555988</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO
. COVID‐19 ‐ Landscape of novel coronavirus candidate vaccine development worldwide. 2022.  Accessed October 28, 2022. https://www.who.int/publications/m/item/draft‐landscape‐of‐covid‐19‐candidate‐vaccines
</Citation></Reference><Reference><Citation>Fang E, Liu X, Li M, et al. Advances in COVID‐19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8940982</ArticleId><ArticleId IdType="pubmed">35322018</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof SY, Slezak JM, Puzniak L, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test‐negative case–control study. Lancet Respir Med. 2022;10(7):689‐699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9033225</ArticleId><ArticleId IdType="pubmed">35468336</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplonek P, Fischinger S, Cizmeci D, et al. mRNA‐1273 vaccine‐induced antibodies maintain Fc effector functions across SARS‐CoV‐2 variants of concern. Immunity. 2022;55(2):355‐365.e354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8733218</ArticleId><ArticleId IdType="pubmed">35090580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Zhang R, Qiao S, et al. Omicron SARS‐CoV‐2 neutralization from inactivated and ZF2001 vaccines. New Engl J Med. 2022;387(3):277‐280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9342420</ArticleId><ArticleId IdType="pubmed">35793198</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX‐CoV2373 COVID‐19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899‐1909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091623</ArticleId><ArticleId IdType="pubmed">33951374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramasamy M, Heath P, Green C, et al. A single‐blind, randomised, phase II UK multi‐centre study to determine reactogenicity and immunogenicity of heterologous prime/boost COVID‐19 vaccine schedules – Stage 2. 2021.</Citation></Reference><Reference><Citation>Li Q, Wu J, Nie J, et al. The impact of mutations in SARS‐CoV‐2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284‐1294.e1289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7366990</ArticleId><ArticleId IdType="pubmed">32730807</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines ‐ a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261‐279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5906799</ArticleId><ArticleId IdType="pubmed">29326426</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollet J, Chen WH, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021;170:71‐82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7788321</ArticleId><ArticleId IdType="pubmed">33421475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012;119(24):5640‐5649.</Citation><ArticleIdList><ArticleId IdType="pubmed">22535666</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai N, Min WP, Ichim TE, Wang H, Zhong R. Th1/Th2 xenogenic antibody responses are associated with recipient dendritic cells. Microsurgery. 2007;27(4):234‐239.</Citation><ArticleIdList><ArticleId IdType="pubmed">17477419</ArticleId></ArticleIdList></Reference><Reference><Citation>Manenti A, Gianchecchi E, Dapporto F, et al. Evaluation and correlation between SARS‐CoV‐2 neutralizing and binding antibodies in convalescent and vaccinated subjects. J Immunol Methods. 2022;500:113197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8619878</ArticleId><ArticleId IdType="pubmed">34843712</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Mao Q, Zhang J, et al. Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS‐CoV‐2 variants in mice and macaques. Front Immunol. 2022;13:949248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9428284</ArticleId><ArticleId IdType="pubmed">36059554</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Mao Q, Peng X, et al. Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS‐CoV‐2 variants in non‐human primates. Signal Transduct Target Ther. 2022;7(1):69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8892123</ArticleId><ArticleId IdType="pubmed">35241645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Song Z, Yang J, et al. Transcriptomic analysis of the innate immune signatures of a SARS‐CoV‐2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV. Emerg Microbes Infect. 2022;11(1):1145‐1153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9037177</ArticleId><ArticleId IdType="pubmed">35343384</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen X. Boosting immunity to Omicron. Nat Med. 2022;28(3):445‐446.</Citation><ArticleIdList><ArticleId IdType="pubmed">35210597</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian L, Liu J, Gao F, et al. Research progress on vaccine efficacy against SARS‐CoV‐2 variants of concern. Hum Vaccin Immunother. 2022;18(5):2057161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115786</ArticleId><ArticleId IdType="pubmed">35438600</ArticleId></ArticleIdList></Reference><Reference><Citation>Linares‐Fernández S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends in molecular medicine. 2020;26(3):311‐323.</Citation><ArticleIdList><ArticleId IdType="pubmed">31699497</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalczyk A, Doener F, Zanzinger K, et al. Self‐adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine. 2016;34(33):3882‐3893.</Citation><ArticleIdList><ArticleId IdType="pubmed">27269061</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS‐CoV‐2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double‐blind, placebo‐controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803‐812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906628</ArticleId><ArticleId IdType="pubmed">33548194</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS‐CoV‐2 vaccine in healthy adults aged 18–59 years: a randomised, double‐blind, placebo‐controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181‐192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832443</ArticleId><ArticleId IdType="pubmed">33217362</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Hou L, Guo X, et al. Heterologous AD5‐nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022;28(2):401‐409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863573</ArticleId><ArticleId IdType="pubmed">35087233</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>